Dyukembaio and Neurophet to Develop Brain Disease Diagnostic Platform Combining Radiopharmaceuticals and AI

Aiming to Shorten Waiting Times for Parkinson's and Alzheimer's Diagnosis
Examination Efficiency Expected to Improve by Up to Fourfold

Dyukembaio and Neurophet announced on the 23rd that they have signed a joint development agreement for a degenerative brain disease diagnostic platform that combines radiopharmaceuticals with artificial intelligence (AI).

Dyukem Baio company logo image. Dyukem Baio

The core of this next-generation platform is to enhance the diagnostic efficiency for Parkinson's disease and Alzheimer's disease by integrating AI-based image generation and analysis technology into PET examinations that use radiopharmaceuticals.

Currently, for PET examinations to diagnose Parkinson's disease and Alzheimer's disease, patients must wait 90 to 120 minutes after injection of a radiopharmaceutical until the drug is sufficiently distributed in the brain. Despite the fact that most of the examinees are elderly patients, long waiting times, along with limitations in equipment and manpower, restrict improvements in examination throughput.

In the platform now being developed, AI will predict and generate a high-resolution image corresponding to the time point when drug distribution is completed, using only the initial scan images. This is expected to shorten patient stay time and increase examination throughput by three to four times within the same time frame.

A notable feature is its multi-disease structure, which allows a single AI technology to be applied to both Parkinson's disease and Alzheimer's disease. The platform is also expected to include a function that provides medical staff with a comprehensive interpretation report, by having the AI analyze the degree of radiopharmaceutical uptake in lesions and its changes over time.

Neurophet will be responsible for developing patented "AI early diagnostic image generation and analysis" software and obtaining medical device approvals. Dyukembaio will conduct clinical trials applying this software to its Parkinson's disease diagnostic agent "18F-FP-CIT" and Alzheimer's disease diagnostic agents "Vizamyl" and "Neuraceq," and will pursue domestic and overseas regulatory approvals.

Dyukembaio expects growth in its diagnostic business through increased use of diagnostic agents resulting from improved examination throughput. Neurophet's strategy is to secure an additional revenue base through a convergence model that combines radiopharmaceuticals with AI software.

The two companies plan to promote commercialization in Korea and abroad after completing clinical trials and regulatory approval procedures.